by Tyrosine Kinase Inhibitors Market – Snapshot
The global tyrosine kinase inhibitors market is expanding owing to high prevalence and increase in incidence of cancer across the globe. The global tyrosine kinase inhibitors market was valued at more than US$ 18.0 Bn in 2017 and is projected to surpass US$ 19.0 Bn by 2026, expanding at a negative compound annual growth rate (CAGR) during the forecast period. The global market is witnessing expansion at a relatively higher growth rate owing to increasing expenditure on health care and high prevalence and increase in incidence of cancer across the globe.
Get the sample copy of report@ https://qyresearchmedical.com/sample/111984
Cancer is the unregulated growth of body cells due to genetic mutations in its differentiation regulatory genes. Tyrosine kinases are enzymes that signal the cell differentiation cycle, mutation in their expression genes leads to their over expression, which results in uncontrolled proliferation of cells to form tumors. Tyrosine kinase inhibitors are small molecules that bind to the receptor site of the kinase enzyme available at cell surface. This binding blocks the phosphorylation by blocking adenosine tri-phosphate (ATP) biding to the receptor. Based on type of kinase receptors being targeted, tyrosine kinase inhibitors can be classified into BCR-ABL TKIs, EGFR TKIs, VEGFR TKIs, Janus Kinase Inhibitors, BTK inhibitors.
Tyrosine kinase inhibitors (TKIs) aid patients suffering from different cancer diseases. Tyrosine kinase inhibitors were accepted largely due to specificity and efficacy and the benefits these offer over chemotherapy and radiotherapy. High prevalence and incidence rates of cancer diseases such as chronic myeloid leukemia (CML), lung cancer, breast cancer, and renal cell cancer, and expanding indications of existing and pipeline on TKIs have expanded the indication areas of existing and pipeline on tyrosine kinase inhibitors in order to address various unmet needs and extend the product lifecycle. These factors, collectively, are projected to drive the global tyrosine kinase inhibitors market in the near future. Furthermore, rise in awareness about cancer diagnosis and treatment and surge in adoption in underdeveloped and developing markets are key factors that are estimated to fuel the tyrosine kinase inhibitors market in the near future
The global tyrosine kinase inhibitors market has been broadly segmented based on product, application, distribution channel, and region. In terms of product, the global market has been classified into BCR-ABL tyrosine kinase inhibitor, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, vascular endothelial growth factor (VEGFR) tyrosine kinase inhibitors, and other tyrosine kinase inhibitors. BCR-ABL tyrosine kinase inhibitors were one of the first approved TKIs for cancer treatment. Their wide acceptance and indications have contributed to their significant share in the global market. VEGFR tyrosine kinase inhibitors are projected to be a highly promising class of TKIs. Several companies have developed their VEGFR TKIs drugs with features of multi kinase receptor inhibition. These factors are likely to augment the segment by the end of 2026. In terms of application, lung cancer is the leading cause of cancer deaths in the world. TKIs such as EGFR, ALK, and HGFR have been in use for treating lung cancers. Increase in incidence of lung cancer is likely to propel the segment.
In terms of distribution channel, the global tyrosine kinase inhibitors market has been segregated into hospital pharmacies, independent pharmacies, and online pharmacies. The hospital pharmacies segment is projected to account for a prominent share of the market. International and regional pharmacy service providers are expanding their operations across the regions, this is attributed to strong infrastructure network for distribution, thereby contributing to the dominant share held by the independent pharmacies segment of the global tyrosine kinase inhibitors market. Consolidation among independent pharmacies and their expanding operations across regions are likely to propel the independent pharmacies segment in the global market. Increase in adoption of e-commerce and convenience offered by online pharmacies are expected to drive the adoption of online pharmacies in developed markets.
In terms of region, the global tyrosine kinase inhibitors market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market; however, it is projected to gain market share by the end of 2026. The market in North America is primarily driven by the high cost of TKIs and high health care expenditure, which have contributed to the leading share held by North America. Furthermore, demand for advanced treatment options such as targeted therapies has contributed to the leading share held by the region. Recent patent expiry of several blockbuster TKIs has negatively impacted the market in North America. However, the introduction of new TKIs, such as JAK TKIs, multi-targeted TKIs, ALT TKIs, and others has compensated for the impact, which is projected to fuel the TKIs market in North America during the forecast period. The tyrosine kinase inhibitors market in Asia Pacific is projected to expand at a rapid pace during the forecast period. Rest of Asia Pacific countries dominated the tyrosine kinase inhibitors market in Asia Pacific, while the market in China and India is estimated to expand at a significant CAGR during the forecast period.
Companies such as Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., and Johnson & Johnson accounted for a major share of the global tyrosine kinase inhibitors market in 2017. In May 2018, Pfizer’s XALKORI (crizotinib) received FDA breakthrough therapy designation in two new indications. This is expected to increase the company’s therapy segment research in the near future. Other global players operating in the market include AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., , Eisai Co., Ltd., and Eurofarma Laboratórios S/A, who are focused on strategic acquisitions and collaborations with parallel companies in order to improve and strengthen their geographic presence in the international market.
Presently, commercially available tyrosine kinase inhibitors are indicated for treating non-small cell lung cancer, renal cell cancer, breast cancer, chronic myeloid leukemia, hepatocellular carcinoma, and breast cancer. These drugs are indicated as monotherapy or combination therapy, along with chemotherapy or as post-surgical resection remedy. However, tyrosine kinase inhibitors are not available for other cancer types such as neuroendocrine tumors.
According to the National Cancer Institute of the U.S., around 1,735,350 new cancer cases were diagnosed in the U.S. in 2018. Moreover, the U.S. had 15.5 million cancer survivors in 2016, which is projected to increase to 20.3 million by 2026.
Surge in Adoption in Underdeveloped and Developing Markets
Awareness about cancer diagnosis and treatment is being spread across the globe. Governing bodies are taking initiatives to provide access to healthcare to public at large.
Easing of norms for drug import, initiatives to attract health care providers & pharmaceutical companies to establish their base, and drug pricing regulations are likely to drive the oncology market. This, in turn, is projected to augment the tyrosine kinase inhibitors market.
Availability of generics in underdeveloped and developing markets is anticipated to spur adoption of tyrosine kinase inhibitors
Global tyrosine kinase inhibitors market has been segmented as given below:
By Product
- BCR-ABL Tyrosine Kinase Inhibitors
- Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
- Vascular Endothelial Growth Factor (VEGFR) Tyrosine Kinase Inhibitors
- Other Tyrosine Kinase Inhibitors (Janus Kinase Inhibitors, Bruton’s Kinase Inhibitor, HGFR TKIs, ALK / ROS1 TKIs, etc.)
By Application
- Chronic Myeloid Leukemia (CML)
- Lung Cancer
- Breast Cancer
- Renal Cell Cancer
- Others
By Distribution Channel
- Hospital Pharmacies
- Independent Pharmacies
- Online Pharmacies
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East
- Saudi Arabia
- UAE
- Rest of Middle East
- Africa
- South Africa
- Rest of Africa
Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111984/2900
